Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SENSIENT TECHNOLOGIES CORPSXT · Entity 3822 | Director | November 01, 2017 | November 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SENSIENT TECHNOLOGIES CORP
Report date November 01, 2017 · Filed November 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,087.125 |
Last balance in matching sequence
After 2017-11-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-11-01 · Exercise / conversion · Acquired 2,000 · Balance 26,087.125 F1: Exercise of in-the-money stock option that would otherwise expire on 5/1/2018, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F2: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. Row 2 · 2017-11-01 · Sale · Disposed 2,000 · Balance 24,087.125 F2: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.07 · Expires 2018-05-01 | Direct | 0 |
Reported balance
After 2017-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-01 · Exercise / conversion · Disposed 2,000 · Balance 0 F1: Exercise of in-the-money stock option that would otherwise expire on 5/1/2018, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F3: Original option grant vests in three equal annual installments beginning on the date listed in the "Date Exercisable" column. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercise of in-the-money stock option that would otherwise expire on 5/1/2018, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e).
F2: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan.
F3: Original option grant vests in three equal annual installments beginning on the date listed in the "Date Exercisable" column.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2017 Filed Nov 2, 2017 20:07 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $30.07 | $0.00 |
DisclosureSEC source: 0001127602-17-030951 · form4.xml · derivative · entry 3 CLYDESDALE FERGUS M · CIK 0001200339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of in-the-money stock option that would otherwise expire on 5/1/2018, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F1 · shares: Exercise of in-the-money stock option that would otherwise expire on 5/1/2018, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F3 · derivative.exercise_date: Original option grant vests in three equal annual installments beginning on the date listed in the "Date Exercisable" column. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:07 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | SaleCommon Stock | 2,000 | $76.00 | $152,000.00 |
DisclosureSEC source: 0001127602-17-030951 · form4.xml · nonDerivative · entry 2 CLYDESDALE FERGUS M · CIK 0001200339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,087.125 F2 · balance_after: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:07 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | Exercise / conversionCommon Stock | 2,000 | $30.07 | $60,140.00 |
DisclosureSEC source: 0001127602-17-030951 · form4.xml · nonDerivative · entry 1 CLYDESDALE FERGUS M · CIK 0001200339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,087.125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of in-the-money stock option that would otherwise expire on 5/1/2018, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F1 · shares: Exercise of in-the-money stock option that would otherwise expire on 5/1/2018, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F2 · balance_after: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:36 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | GrantCommon Stock | 1,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-015905 · form4.xml · nonDerivative · entry 1 CLYDESDALE FERGUS M · CIK 0001200339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,917.168 F1 · kind: Represents grant of restricted stock under Issuer's 2012 Non-Employee Directors Stock Plan. F1 · price: Represents grant of restricted stock under Issuer's 2012 Non-Employee Directors Stock Plan. F2 · balance_after: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 21:27 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $26.12 | $0.00 |
DisclosureSEC source: 0001127602-16-066400 · form4.xml · derivative · entry 3 CLYDESDALE FERGUS M · CIK 0001200339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2017-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of in-the-money stock option that would otherwise expire on 5/1/2017, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F1 · shares: Exercise of in-the-money stock option that would otherwise expire on 5/1/2017, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F4 · derivative.exercise_date: Original option grant vests in three equal annual installments beginning on the date listed in the "Date Exercisable" column. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 21:27 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | SaleCommon Stock | 2,000 | $74.49 | $148,980.40 |
DisclosureSEC source: 0001127602-16-066400 · form4.xml · nonDerivative · entry 2 CLYDESDALE FERGUS M · CIK 0001200339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,681.755 F3 · price: This amount represents the weighted average sale price for the transactions reported on this line. The actual sale prices ranged from $74.48 to $74.52. The reporting person hereby agrees to provide, upon request by the SEC staff, by the Issuer, or by any security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. Read SEC document |
| November 07, 2016 Filed Nov 8, 2016 21:27 UTC | SENSIENT TECHNOLOGIES CORP SXT · Entity 3822 | Exercise / conversionCommon Stock | 2,000 | $26.12 | $52,240.00 |
DisclosureSEC source: 0001127602-16-066400 · form4.xml · nonDerivative · entry 1 CLYDESDALE FERGUS M · CIK 0001200339 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,681.755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of in-the-money stock option that would otherwise expire on 5/1/2017, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F1 · shares: Exercise of in-the-money stock option that would otherwise expire on 5/1/2017, exempt from Section 16(b) by virtue of Rule 16b-6(b) and Rule 16b-3(d) and (e). F2 · balance_after: Includes shares of restricted stock held under Issuer's 2012 Non-Employee Directors Stock Plan, and shares held in a dividend reinvestment plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.